The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (Averse = aim to avoid the risk entirely; Minimal = insistence on low risk options; Cautious = preference for low risk options; Open = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) Management (those responsible for the area reported on); (2) Risk and compliance functions (internal but independent of the area reported on); and (3) Independent assurance (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales

Key to lead committee assurance ratings:

- Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity - no gaps in assurance or control AND current exposure risk rating = target OR

 - gaps in control and assurance are being addressed
 - Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy
 - Red = Negative assurance: the Committee is satisfied that there is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the nature and/or scale of the threat or opportunity

This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.

Reference	Principal risk	Lead committee	Initial date of assessment	Last reviewed	Target risk score C x L	Previous risk score (at previous review/update) C x L	Current risk score C x L
PR1	Significant deterioration in standards of safety and care	Medical Director	01/04/2018	12/07/2021	4 x 2 = 8	4 x 5 = 20	4 x 4 = 16
PR2	Demand that overwhelms capacity	Chief Operating Officer	01/04/2018	12/07/2021	4 x 2 = 8	4 x 5 = 20	4 x 4 = 16
PR3	Critical shortage of workforce capacity and capability	Director of People	01/04/2018	29/07/2021	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR4	Failure to achieve the Trust's financial strategy	Chief Financial Officer	01/04/2018	27/07/2021	4 x 2 = 8	5 x 3 = 15	5 x 3 = 15
PR5	Inability to initiate and implement evidenced based improvement and innovation	Director of Culture & Improvement	17/03/2020	29/07/2021	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9
PR6	Working more closely with local health and care partners does not fully deliver the required benefits	Chief Executive Officer	01/04/2020	13/07/2021	2 x 2 = 4	2 x 3 = 6	2 x 3 = 6
PR7	Major disruptive incident	Director of Corporate Affairs	01/04/2018	13/07/2021	4 x 1 = 4	4 x 2 = 8	4 x 2 = 8

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:



	Principal risk (what could prevent us achieving this strategic priority)	•	on in standards of	in standards of safe safety and quality of patimes	•	Trust resulting in su	ubstantial incidents of		Strat	egic priority	1. To pro
	Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient harm	25 - 20 -		
	Executive lead	Medical Director	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	15 -		
	Initial date of assessment	01/04/2018	Likelihood	5. Very likely 4. Somewhat likely	3. Possible	2. Unlikely			10 - 5 -		
l	Last reviewed	12/07/2021	Risk rating	20. <u>16.</u> Significant	12. High	8. Medium			0 -	Aug-20 Sep-20 Oct-20 Nov-20	-21
	Last changed	12/07/2021								Aug Sep Oct Nov	Jan Fah

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)
A widespread loss of organisational focus on patient safety and quality of care leading to increased incidence of avoidable harm, exposure to 'Never Events', higher than expected mortality, and significant reduction in patient satisfaction	 Clinical service structures, accountability & quality governance arrangements at Trust, division & service levels including: Monthly meeting of Patient Safety Committee (PSC) with work programme aligned to CQC registration regulations Advancing Quality Programme and AQP oversight group Nursing and Midwifery and AHP Business meeting Clinical policies, procedures, guidelines, pathways, supporting documentation & IT systems Clinical audit programme & monitoring arrangements Clinical staff recruitment, induction, mandatory training, registration & re-validation Defined safe medical & nurse staffing levels for all wards & departments (Nursing safeguards monitored by Chief Nurse) Ward assurance/ metrics and accreditation programme Nursing & Midwifery Strategy AchP Strategy Scoping and sign-off process for incidents and Sis Internal Reviews against External National Reports Getting it Right First Time (GIRFT) localised deep dives, reports and action plans CQC Bi-monthly Engagement Meetings 	Intranet currently contains some out of date clinical information that may still be accessible Lack of real time data collection	Intranet documents review SLT Lead: Head of Communications Timescale: end March September 2021 Information, EMPA, EPR and IT Developments in development or progress SLT Lead: Medical Director Timescale: March 2022	Management: Learning from deaths Report to QC and Board; Quarterly Strategic Priority Report to Board; Divisional risk reports to Risk Committee bi-annually; Guardian of Safe Working report to Board qrtly Quality and Governance Reporting Pathway; Patient Safety Committee →Quality Committee reports include: - DPR Report to PSC monthly and QC bi-monthly - PSC assurance report to QC bi-monthly - Patient Safety Culture (PSC) programme - EoLC Annual Report to QC - Safeguarding Annual Report to QC - CYPP report to QC quarterly - Medical Education update report to QC - Medicial Education Annual Report to QC - Medicines Optimisation Annual Report (Oct 2020) - National Audit for Care of end of Life (Sep 2020) - Ockenden Report (Dec 2020) Risk & compliance: Quality Dashboard and SOF to PSC Monthly; Quality Account Report dtrly to PSC and QC; SI & Duty of Candour report to RC monthly: CQC report to QC Inspection Report 2020 Screening Quality Assurance Services assessments and reports of: - Antenatal and New-born screening Breast Cancer Screening Services - Bowel Cancer Screening Servi



ovi	de outstanding care	
Feb-21		rent risk level erable risk el
	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
ly		
y ty SC	None	Positive

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
An outbreak of infectious disease (such as pandemic influenza; Coronavirus; norovirus; infections resistant to antibiotics) that forces closure of one or more areas of the hospital	 Infection prevention & control (IPC) programme Policies/ Procedures; Staff training; Environmental cleaning audits PFI arrangements for cleaning services Root Cause Analysis and Root Cause Analysis Group Reports from Public Health England received and acted upon Infection control annual plan developed in line with the Hygiene Code Influenza and Covid vaccination programmes Public communications re: norovirus and infectious diseases Coronavirus identification and management process Infection Prevention and Control Board Assurance Framework Outbreak meeting including external representation, CCG, PHE, Regional IPC CQC IPC Key lines of enquiry engagement sessions 	None	N/A	Management: Divisional reports to IPC Committee (every 6 weeks); IPC Annual Report to QC and Board; Water Safety Group; IPC BAF report to PSC and QC Risk & compliance: IPC Committee report to PSC qtrly; SOF Performance Report to Board monthly; IPC Clinical audits in IPCC report to PSC qtrly Independent assurance: Internal audit plan; CQC Rating Good with Outstanding for Care May '20; PLACE Assessment and Scores Estates Governance bi-monthly; Public Health England attendance at IPC Committee; Influenza vaccination cumulative number of staff vaccinated; HSE visit Dec '20 – no concerns highlighted IPC BAF Peer Review by Medway Trust HSE External assessment and report HSIB IPC assessment and report	Learning from the impact on activity, patient safety and staffing due to COVID-19 wave 1 Constraints of critical care capacity and PPE availability dependent on the size of future waves and restoration activity Business case to enhance oxygen capacity/flow has been delivered – awaiting further instruction from NHSE/I <u>Unable to provide assurance</u> that infection risk is monitored at the front door and documented in the patient notes <u>Information capture to be</u> moved onto the electronic patient record <u>SLT Lead: Chief Nurse</u> Timescale: March 2022	Inconclusiv



Principal risk (what could prevent us achieving this strategic priority)	PR 2: Demand that ov Demand for services that over care		Strat	egic priority	1. To pro					
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient harm	25		
Executive lead	Chief Operating Officer	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	20 -		
Initial date of assessment	01/04/2018	Likelihood	5. Very likely 4. Somewhat likely	4. Somewhat likely	2. Unlikely			10 -	•••••	
Last reviewed	12/07/2021	Risk rating	20. <u>16.</u> Significant	16. Significant	8. Medium			0 -	ug-20 ep-20 0ct-20	-20 -20 -21
Last changed	12/07/2021								Aug-20 Sep-20 Oct-20	Jan- Jan-

(what could prevent us achieving this strategic priority)																									
Lead Committee	Quality	Risk rating	Current exposure Tolerabl	e Ta	rget	Risk type	Patient harm	25																	
Executive lead	Chief Operating Officer	Consequence	4. High 4. High	4.	High	Risk appetite	Minimal	20 15			Curr	ent risk level													
Initial date of assessment	01/04/2018	Likelihood	5. Very likely 4. Somewhat likely4. Somewhat	what likely 2.	Unlikely			10				rable risk level													
Last reviewed	12/07/2021	Risk rating	20. 16. Significant 16. Significant 8. Medium 0 07 07 0						21 22	ਸ਼ ਸ਼ ਸ਼ ਸ਼															
Last changed	12/07/2021								Aug- Sep- Oct- Nov-	Jan- Feb-	Apr- May- Jul- Jul-														
the risk and reducing the likelihood Threat: Growth in demand • Emergency admission and		ns & processes do we alre he likelihood/ impact of th		Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level) Pobust delivery of		ans to improve ntrol e further controls possible in er to reduce risk exposure nin tolerable range?) -going discussions	(<u>Evidence</u> that the reliance on are effe	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)			Gaps in assurance / actions to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating													
for care caused by an population (forecast increase in emergend demand of 4-5% per reduced social care f and increased acuity to more admissions a longer length of stay reduction in capacity current and future do due to the impact of 19	 ageing Single streamin with NEMs Trust and Syste Trust and Syste Trust leadershi Leading Patient pathwa Inter-profession to meet Proactive syste Together Alliar COVID- Patient Flow Prostive syste SFH internal W Referral manage Carcer si Risk assessmer Elective Steerin elective waitin Accelerator Pre- national Elective 	ng process for ED & P em escalation process ement plan p of and attendance ay, some of which are nal standards across liagnostics are compl em leadership engage nce Delivery Board rogramme inter capacity plan & gement systems share lent planning and gov ervices maintained do the to prioritise individu of Group now meetin g times ogramme — SFH has b we Accelerator progra	rimary Care – regular meetings at A&E Board joint with NUH the Trust to ensure turnaround eted within 1 day ment from SFH into Better Mid Notts system capacity plan ed between primary and secondary vernance process uring COVID-19 dual patients ing monthly to steer the recovery of meen successful in being part of the mme attracting £2.5m of funding rvices	Robust delivery of the demand management schemes across the system		-going discussions oss ICS and specifically th NUH to describe ure service delivery. Intinued development of clinical service ategy, Tomorrow's NUH fresh NUH/SFH Exec to ec forum nonthly progress dates to Board Lead: Medical Director nescale: end March 21 mplete CS Clinical Services ategy work completed – wing on to plementation	arrangements Executive Team to Exec meetin to Board; Plann clear demand a and capturing 19 Pandemic re Recovery Plan Report to Reco Steering Group Risk & complia Committee bi-a monthly; Single Monthly Perfor Control Team g Cancer services Independent a Team review o	Management: Performance management reporting arrangements between Divisions, Service Lines and Executive Team; Winter Plan to Board Oct '20; Exec to Exec meetings; Cancer 62 day improvement plan to Board; Planning documents for 19/20 to identify clear demand and capacity gaps/bridges; Identifying and capturing Potential Harm Resultant from COVID- 19 Pandemic report to Board Jun '20; COVID-19 Recovery Plan to Board Sep '20; Elective Services Report to Recovery Committee monthly <u>; Elective Steering Group report to Executive Team weekly</u> Risk & compliance: Divisional risk reports to Risk Committee bi-annually; Significant Risk Report to RC monthly; Single Oversight Framework Integrated Monthly Performance Report to Board; Incident Control Team governance structure to TMT Mar '20 <u>;</u> Cancer services report to Board Jun '21 Independent assurance: NHSI Intensive Support Team review of cancer processes May '20				Positive													
Operational failure o Practice to cope with resulting in even high demand for seconda	 Visibility on the CCG risk register/BAF entry relating to operational failure of General Practice Visibility on the CCG risk register/BAF entry relating to operational failure of General Practice Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Weekly Executive meeting with the CCGs Weekly Mid Notts Network Calls 		 failure of General Practice Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Weekly Executive meeting with the CCGs 		failure of General Practice Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Weekly Executive meeting with the CCGs		failure of General Practice Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Weekly Executive meeting with the CCGs		 failure of General Practice Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Weekly Executive meeting with the CCGs 				CCG and SFH ri to risks for prin Independent a	Management: Routine mechanism for sharing of CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand Independent assurance: 'Drivers of demand' discussed at Board Aug '19		G and SFH risk registers – particularly with regard risks for primary care staffing and demand lependent assurance: 'Drivers of demand'		CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand Independent assurance: 'Drivers of demand'		CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand Independent assurance: 'Drivers of demand'		CCG and SFH risk registers – particularly with regard o risks for primary care staffing and demand ndependent assurance: 'Drivers of demand' liscussed at Board Aug '19 SLT Le Times		Lack of recent GP vacancy rates data received from Primary Care Pursue current GP vacancy data SLT Lead: COO Timescale: end March '21 <u>- complete</u>	Inconclusive
 Threat & Opportunity: Drop in operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development Horizon scanning with neighbour organisations via meetings between relevant Executive Directors Weekly management meeting with the Service Director from Notts H0 Bilateral work – Strategic Partnership forum 			None	N//	Ą	partnership for	um mi	: Divisional NUH/ inutes and action H paper to Execu	log; NUH	Lack of control over the flow of patients from the surrounding area	Inconclusive														



Principal risk (what could prevent us achieving this strategic priority)	A shortage of wo	-	and capability re	pacity and capabil sulting in a deterioratio	-	f staff experience,	moral	e and well	-being which can		Stra	tegic priority	3: To r
Lead Committee	People, Culture	& Improvement	Risk rating	Current exposure	То	lerable	Targ	et	Risk type	Services	25		
Executive lead	Director of Peop	ole	Consequence	4. High	4.	High	4. Hi	gh	Risk appetite	Cautious	20		
Initial date of assessment	01/04/2018		Likelihood	4. Somewhat likely	4.	Somewhat likely	2. Ur	nlikely			10 5	·····	• • • • • • • • • •
Last reviewed	29/07/2021		Risk rating	16. Significant	16	. Significant	8. M	edium			0	Aug-20 Sep-20 Oct-20	Dec-20 Jan-21
Last changed	29/07/2021											Aug Sep	Dec
Strategic threat (what might cause this t			ms & processes do we	already have in place to assist us d/ impact of the threat)	s in	Gaps in contro (Specific areas / issue further work is requir manage the risk to ac appetite/ tolerance le	s where ed to cepted	(are further	controls possible in luce risk exposure within nge?)	Sources of assur (<u>Evidence</u> that the correliance on are effect	ontrols/		are placing
Threat: Inability to staff due to demog (including a significa external factors and circumstances) and attitudes to careers employment marker reduced availability competition), or more relating to the work resulting in critical w some clinical service	raphic changes ant impact of d/or unforeseen shifting cultural , combined with t factors (such as and increased ental health issues sing environment, workforce gaps in	 People and Im Culture and Im Medical and N Activity, Work 2 year workfor Group and rev workforce mo Vacancy mana processes TRAC system f procedures us Defined safe r departments , Temporary sta defined autho Education par Director of Pe Workforce pla Communication pensions and Pensions restring 	nprovement Cabin Jursing task force force and Financia rce plan supported view processes (con delling; winter cap agement and recru for recruitment; e- sed to plan staff uti nedical & nurse sta / Safe Staffing Stan affing approval and strisation levels tnerships ople attendance at nning for system v ons issued regardin provision of pensic ructuring payment nts for at-risk staff	et I plan I by Workforce Planning isultant job planning; acity plans) itment systems and Rostering systems and lisation iffing levels for all wards a dard Operating Procedure recruitment processes with People and Culture Board vork stream g HMRC taxation rules on ons advice introduced groups	e ith d	Lack of Divisional ownership and understanding of workforce issues		and Impr (People a SLT Lead : of People	e People, Culture ovement Strategy nd Inclusion) Executive Director e: March 2022	Management: N 2018/20; Quarte Board; AHP Strat Midwifery and A Nov 20; Workfor quarterly; Quarte & Inclusion and C Culture and Impi Culture and Impi '20; Recruitment Risk and complia risk report Mont report Risk Comr (Monthly); Bank Guardian of safe Independent ass use of resources Retention report EU Exit Risk Syste Nottinghamshire Checks internal a assurance; HSJ A 2021	rly Str egy to HP six ce and erly As Culture over a Ret ince: f hly; HF hly; HF hly; HF nittee and ag worki uranc report Jan '1 em Ov Syste oudit ro	ategic Priority F Board Sep '19; monthly staffir OD ICS/ICP up surance report e & Improveme ent Committee ent: COVID-19 ention report r Risk Committee & Workforce ; SOF – Workfo gency report (m ng report to Bo e: Well-led report ; IA Recruitmen 9 – Significant erview – Nottir m Dec '20; Pre- eport Feb '21 –	Report to ; Nursing a ng report date s on Peop ent to Peop ; People Update M monthly significar planning rce Indica nonthly); ort CQC; N nt & Assurance employm significan
productivity arising reduction in staff av reduction in effort a contractual require substantial proport workforce and/or lo colleagues from the caused by other fac job satisfaction, lac for personal develo pay restraint, workf	 nd/or loss of experienced Schwartz rounds Learning from COVID Staff morale identified as 'profile risk' in Divisional risk registers Star of the month/ milestone events t, workforce fatigue or Star of the month/ milestone events Divisional action plans from staff survey Policies (inc. staff development; appraisal process; sickness 		S	Inequalities in sta inclusivity and wellbeing across protected characteristics gro		and Impr (Culture a SLT Lead: of People Timescale Deliver th and Inclu SLT Lead: of People	e: March 2022 ne Equality, Diversity sivity Strategy Executive Director	Management: St report to Board (Annual report Ju Board Jun '20;Co addressing; D&I, Oct 20 Board; Qu People & Inclusio People Culture a People Culture a Update May '20; to Board Aug '20 post exercise rep Committee (rolli Risk and compli	Oct '20 mbine Violer arterl on and nd Imp fqual ; Busir ports th ng pro); Diversity & In WRES and WDE ed assurance re- nce & Aggressio y Assurance re- Culture & Imp provement Con provement: CO ity & Diversity p ness Continuity nrough Resilien gram)	nclusion S report t port on, Restrai ports on rovement nmittee; VID-19 presentat exercises ice Assura		



o maxir	nise the potential of our workfor	ce
Jan-21 Feb-21 Mar-21	Tolerab	t risk level ble risk level risk level
ing	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
/ to ng and ort – eople le e May y cant ng licators /); ov '20 C; NHSI nce; and yyment cant Year	Staff becoming infected, leading to increased sickness absence Staff working in unfamiliar roles <u>Staff mental health issues as a</u> <u>result of psychological trauma</u>	Inconclusive
annual n rt to traints on ent to e; tation ses – urance ally);	Reduction in available staff due to COVID-19, e.g. staff isolating, shielding of vulnerable staff groups and social distancing; redeployment to the vaccination programme Reduction in effort above and beyond contractual requirements due to COVID-19 service restrictions Reluctance of some staff members to return to work due	Inconclusive

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
line with desired culture This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to empower patients and carers to enable personalised patient centred care	 Just and restorative culture Influenza vaccination programme COVID-19 vaccination programme Staff wellbeing drop-in sessions Staff counselling / Occ Health support Enhanced equality, diversity and inclusion focus on workforce demographics Freedom to Speak Up Guardian and champion networks Emergency Planning, Resilience & Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event) Combined violence and aggression campaign across system partners 			Freedom to speak up self-review Board Oct '20; Freedom to Speak Up Guardian report quarterly; Guardian of Safe Working report to Board Dec '20; Gender Pay Gap report to Board Mar '20; TRAC Performance Report to P, OD&C quarterly; Interim NHS People Plan self-assessment to People Culture & Inclusion Sep '20; Significant Risk Report to RC monthly; Gender Pay Gap report to Board Apr '21 Independent assurance: National Staff Survey Mar '21; SFFT/Pulse surveys (Quarterly); Well-led report CQC	to COVID-19-associated health concerns Restrictions to deployment of key staff due to reduced availability of Mandatory and Statutory Training, and the consequential expiry of certification <u>Increase in violence and</u> aggression towards staff <u>Implement the</u> recommendations from the SWE <u>Expert Group report 'Violence &</u> Aggression and Associated Risks' <u>SLT Lead: Chief Nurse</u> <u>Timescale: March 2022</u>	



Principal risk (what could prevent us achieving this strategic priority)	PR 4: Failure to achiev Failure to achieve agreed tra		07					Strat prior	-	5: To ac
Lead Committee	Finance	Risk rating	Current exposure	Tolerable	Target	Risk type	Regulatory action	20 -		
Executive lead	Chief Financial Officer	Consequence	5. Very high	4. High	4. High	Risk appetite	Cautious	15 -		
Initial date of assessment	01/04/2018	Likelihood	3. Possible	3. Possible	2. Unlikely			10 - 5 -	•••••	
Last reviewed	27/07/2021	Risk rating	15. Significant	12. High	8. Medium			0 -	20	20
Last changed	27/07/2021								Aug-20 Sep-20 Oct-20	Nov-2 Dec-2


(what could prevent us achieving this strategic priority)	Failure to achieve agreed trajectories resulting in regulatory action									Strategic priority	5: To achieve better value			
Lead Committee	Finance		Risk rating	Current exposure	Tolerable	Target	Ris	sk type	Regulatory action	20	<u>.</u>	_		
Executive lead	Chief Financial	Officer	Consequence	5. Very high	4. High	4. High	Ris	sk appetite	Cautious				ent risk level	
Initial date of assessment	01/04/2018		Likelihood	3. Possible	3. Possible	2. Unlike	ely			10 5	Tolerable			
Last reviewed	27/07/2021		Risk rating	15. Significant	12. High	8. Mediu	um				20 27 27 27 27 27 27 20 20	Target	risk level	
Last changed	27/07/2021									Aug-7 Sep-7	Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 May-21 Jun-21	2		
Strategic threat (what might cause this to			systems & processes do	we already have in place to assist kelihood/ impact of the threat)	us (are further cor in order to redu exposure withir range?)	ntrols possible ace risk	Plans to im	nprove control		Sources of assur (<u>Evidence</u> that the c placing reliance on a	ontrols/ systems which we are	Gaps in assurance / actions to address gaps	Assurance rating	
Threat: A reduction change in financial t unexpected event re increased Financial Plan (FIP) requirement the scale of the fina without having an a on quality and safet	trajectory or resulting in an Improvement ent to reduce ancial deficit, adverse impact	 Working ca arrangeme Annual pla reduction of the PFI ber Engageme Transform processes Delivery of enhancem A full 'wasl engageme approved a Medical Pa Close work planning, t Executive of All costs ar funded in f 2021/22 P 	in, including contro of underlying finan nefit by £0.5m annu- nt with the Better ation and Efficiency and PMO coordina f budget holder trai- ents to financial re h up' of portfolio p nt conducted; reco & governance in pla ay Task Force action king with ICS partne- cransformation and oversight of commi- nd required cash as full for period 1/4/2	ugh agreed Ioan of total consideration; cial deficit and unwinding o ually Together alliance programm y Cabinet, FIP planning tion of delivery ining workshops and porting lanning, delivery and overy plan in place, Board ace n plan in place ers to identify system-wide cost reductions itments ssociated with COVID-19 20 to 30/9/20 onfirms continuation of	No long tern commitmen for liquidity support f	t received / cash tification of es for livery of FIP	NHSI required SLT Lead: Chie Timescale: 20 NHSI) Full review of FIP within fina SLT Lead: Dire Timescale: 20 NHSI) H1 and H2 bu include enhar SLT Lead: Chie	d future trajectori ief Financial Office 021/22 H2 plan su f ability to improv ancial planning fo ector of Culture a 021/22 H2 plan su udget setting proc nced confirm and ief Financial Office	er Ibmission date (TBC by e recurrent delivery of r 2021/22 nd Improvement Ibmission date (TBC by eess for 2021/22 to challenge	financial positio FIP Summary (N Priority Report Report & STP FII meeting); Invest programme; Div Committee bi-ar Risk and compli significant risk re Independent as <u>Report of</u> FIP/ Q EY Financial Rec	ance: Risk Committee	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusive	
Threat: ICS system of a negative financial Trust		 Full partici SFH plan co ICS DoFs G 	pation in ICS plann onsistency with ICS	ing 5 plan	ICS underlyir deficit	ng financial	Financial Stra SLT Lead: Chi	ief Financial Office	payment mechanisms		ance: ICS financial reports to tee; ICS Board updates to SFH	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusive	



Principal risk (what could prevent us achieving this strategic priority)	PR 5: Inability to initiate and i Lack of support, capability and agility to		Strate	egic priority	4: To cont					
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient Harm	10 8		
Executive lead	Director of Culture & Improvement	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk appetite	Cautious	6 -		
Initial date of assessment	17/03/2020	Likelihood	3. Possible	3. Possible	2. Unlikely			4 -		
Last reviewed	29/07/2021	Risk rating	9. Medium	9. Medium	6. Low			0 -	0 0 0 0	2 2 1 1
Last changed	29/07/2021								Aug-20 Sep-20 Oct-20	Dec-2 Jan-2 Feb-2

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (<u>Evidence</u> that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	 Digital Strategy Improvement Strategy People, Culture & Improvement Committee Leadership development programmes Talent management map Programme Management Office Culture & Improvement Cabinet Transformation Cabinet Ideas generator platform 		Introduction of a newly designed QI training offer SLT Lead: Director of Culture and Improvement Timescale: May 2021complete Proposal for Continuous Improvement in SFH SLT Lead: Director of Culture and Improvement Timescale: May 2021complete Establishment of an Innovation Hub SLT Lead: Director of Culture and Improvement Timescale: June 2021October 2021 Recruit a Chief Information Officer SLT Lead: Medical Director Timescale: August 2021January 2022	Management: Monthly Transformation and Efficiency report to FC; Clinical Audit & Improvement report to PSC quarterly; Culture & Improvement Assurance Report to PC&IC bi- monthly Risk and compliance: SOF Culture and Improvement indicators; SFH breakthrough objectives to Board quarterly Independent assurance: none currently in place	Delays in training, planned improvement and innovation programmes due to COVID-19 Lack of independent assurance, evidence and insight Development of a Continuous Improvement Maturity Assessment in conjunction with EMAHSN SLT Lead: Director of Culture and Improvement Timescale: December 2021	Positive





Principal risk (what could prevent us achieving this strategic priority)	PR 6: Working more close required benefits Influencing the wider determinar working. This may be difficult bec		Strat	egic priority	2: To pro					
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	10 -		
Executive lead	Chief Executive Officer	Consequence	2. Low	2. Low	2. Low	Risk appetite	Cautious	6 -		
Initial date of assessment	01/04/2020	Likelihood	3. Possible	4. Possible	2. Unlikely		•	4 -		
Last reviewed	13/07/2021	Risk rating	6. Low	8. Medium	4. Low			0 -	Aug-20 Sep-20 Oct-20	-20 -21
Last changed	13/07/2021								Aug: Sep Oct-	Dec

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we a are effective)
Threat: Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care	 Mid-Nottinghamshire Integrated Care Partnership Board Mid-Nottinghamshire ICP Executive formed May 2020 Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020 Nottingham and Nottinghamshire Integrated Care System Board Continued engagement with ICP and ICS planning and governance arrangements Quarterly ICS performance review with NHSI Joint development of plans at ICS level Finance Directors Group ICS Planning Group Alignment of Trust, ICS and ICP plans Trust CFO role as ICS Finance Director Independent chair for ICP ICS Transition and Risk Committee Approved implementation plan for establishing system risk arrangements 	Continued misalignment in organisational priorities Exec to Exec meetings with mid- Nottinghamshire CCG and Nottinghamshire Healthcare have been paused – attempting to re-start	ICS governance review to include: - Roles and responsibilities of the ICS Board - Governance manual - New ICS Chair started in February 2021 SLT Lead: Chief Executive Officer Timescale: under review June 2021 Meetings are now taking place - complete Restore Exec to Exec meetings with mid- Nottinghamshire CCG and Nottinghamshire Healthcare SLT Lead: Chief Executive Officer Timescale: Board to Board with Notts Healthcare agreed for early April 2021. CEO and Chair of NUH, NHC and SFH met in February. Meetings are now taking place - complete	Management: Alliance Development S Strategic Partnerships Update to Board Nottinghamshire ICP delivery report to schedule); Finance Committee report t Nottingham and Nottinghamshire ICS L Summary Briefing to Board; Planning U Risk & compliance: Significant Risk Rep Independent assurance: 360 Assurance readiness to play a full part in the ICS – Assurance
Threat and Opportunity: Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities	 Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP Clinical Services Strategy - <u>510</u> of 20 services complete 	Insufficient granularity of plans to meet the needs of the population and the statutory obligations of each individual organisation	Development of a co-produced clinical services strategy for the ICS footprint – 2 nd set of 5 services SLT Lead: Medical Director 5 of 20 services complete as at October 2019 Timescale: end June 2021 Progress: Update took place at Trust Board workshop 29 April 2021 - complete <u>Development of a co-produced clinical</u> <u>services strategy for the ICS footprint – 3rd</u> <u>set of 5 services</u> SLT Lead: Medical Director Timescale: end September 2021	Management: Alliance Development S Strategic Partnerships Update to Board Nottinghamshire ICP delivery report to schedule); Finance Committee report to Update to Board Independent assurance: none current



omote and support h	ealth and wellbeing	5
Feb-21 Mar-21 May-21 Jun-21		
e are placing reliance on	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Summary to Board; rd; mid- to FC (as meeting to Board; Leadership Board Update to Board eport to RC monthly ice review of SFH – Significant	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive Positive
Summary to Board; rd; mid- to FC (as meeting to Board; Planning tly in place	Delay in delivering the benefits of system working due to the impact of COVID-19	Inconclusive Positive

Principal risk (what could prevent us achieving this strategic priority)	PR 7: Major disruptive in A major incident resulting in tem Trust, which also impacts signific	cident porary hospital clo	osure or a prolon health service co		e continuity of co	re services acro	ss the		Stra	tegic priority	1:1	To provide outstanding care	
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type		Services	15				
Executive lead	Director of Corporate Affairs	Consequence	4. High	4. High	4. High	Risk appetite		Cautious	10			Current	risk level
Initial date of assessment	01/04/2018	Likelihood	2. Unlikely	3. Possible	1. Very unlikely				5		••••	Tolerable	
Last reviewed	13/07/2021	Risk rating	8. Medium	12. High	4. Low				0	g-20 -20 t-20	v-20 c-20	Jan-21 Feb-21 May-21 Jun-21 Jul-21	
Last changed	13/07/2021									Sel Au	De No	Ap A	
Strategic threat (what might cause this to				Gaps in control (are further controls po in order to reduce risk exposure within tolerab range?)	(are further cor	ntrols possible in e risk exposure	(Evidence	of assurance (an that the controls/ sys n are effective)			3	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Shut down IT network due to a scale cyber-attack o system failure that limits the availabilit essential informatio prolonged period	large- orNHIS Cyber Security StrorCyber Security Program Group and work plany ofCyber news – circulated	rategy nme Board & Cyber S d to all NHIS partners cked after 50 days of if not used place cises carried out by 3	Security Project s inactivity – 60 Assurance				submiss complia Board m quarter Cyber So '20 Indeper Security Assuran Manage Cyber So the NHS '21- Sigr <u>Governa</u> assuran	ement: Data Prote sion to Board Mar- ince; Hygiene Rep nonthly; NHIS repo- ly; IG Bi-annual re ecurity and COVID ndent assurance: Governance Rep- ice; ISO 27001 Info ecurity Survey - Th S Dec '20; CCG Cyb nificant Assurance ance and Interface ce; 360 Assurance ion Toolkit audit N Ce	20 Ap ort to 0 ort to F port to 0-19 Re 360 As ort Jan ormation; TIAN ne imposer Sec ; <u>360 A</u> 2 audit 2 Data	r <u>'21</u> - 100% Cyber Security Risk Committee Risk Committee Risk Committee Surance Cyber '19 – Significa on Security I / 360 Assurar act of Covid-19 urity Report M <u>ssurance NHIS</u> – limited Security and	e ee; May nt nce on lar	Insufficient assurance regarding governance and interface with NHIS 360 Assurance internal audit of governance and interface – final report in draft SLT Lead: Medical Director Timescale: February 2021 <u>complete</u> Implement the actions from the NHIS Governance and Interface internal audit report SLT Lead: Medical Director Timescale: March 2022 Cyber Security Essentials Plus mandatory requirement will not be met by June 2021 Address Cyber Security Essentials Plus failures to obtain certification SLT Lead: Director of NHIS Timescale: July 2021	Positive
Threat: A critical infrastructure failur caused by an interr to the supply of one more utilities (elect gas, water), an uncontrolled fire or security incident or of the built environ that renders a signi proportion of the e inaccessible or unserviceable, disru services for a prolog period	uptionPFI Contract and Estatee orPartnersricity,Fire Safety StrategyNHS Supply Chain resiliEmergency Preparednefailurearrangements at regiormentOperational strategiesficantincident (e.g. industrialstatedisease; power failure;CBRNe)Gold, Silver, Bronze cor	2025 es Governance arrang ence planning ess, Resilience & Resp nal, Trust, division an & plans for specific t action; fuel shortag severe winter weath mmand structure for nergency Planning & ommittee (RAC) over ng Engineer (Water)	ponse (EPRR) ad service levels types of major e; pandemic her; evacuation; major incidents security policies	Operational resilier of the Central Steri Services Departme (CSSD)	lethe CSSD serntcase to the ESLT Lead: Di	rvice business Executive team visional nager - Surgery May 2021	plc mon Annual Commit to QC M reports Risk & c to Risk (Indeper Model t standar Assuran Liaison (indeper	ement: Central No athly performance Report; Water Saf tee Jul '20; <u>Patien</u> farch '21; Hard an compliance: Mont Committee ident assurance: to RC Dec '18; EPR ds compliance rat ides; Water Safety if Committee Oct '11: ident audit; MEM fication Mar '21	report rety Up <u>t Safet</u> <u>d soft</u> hly Sig Premis R Report report 9; WSP	t; Fire Safety date Report to <u>cy Concerns rep</u> <u>FM assurance</u> nificant Risk Re es Assurance ort; EPRR Core ct '19) – Substa (WSP) to Joint P report – hard	o Risk port eport antial	Insufficient assurance of hard and soft FM contractor performance Monitor hard and soft FM performance and provide periodic assurance reports SLT Lead: Associate Director of Estates & Facilities Timescale: up to end March 2021complete <u>360 Assurance internal audit of contract</u> <u>management</u> <u>SLT Lead:</u> Associate Director of Estates & Facilities <u>Timescale:</u> September 2021	Positive



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	 NHS Supply Chain resilience planning Business Continuity Management System & Core standards CAS alert system – Disruption in supply alerts Major incident plan in place PPE Strategy PPE Winter Forecast 2020/21 EU Exit Preparation Meetings COVID-19 Pandemic Surge Plan Procurement Influenza Pandemic Business Continuity Plan Interim provision for transmission of personal data to the United Kingdom clause within the EU Exit agreement 	None	N/A	Management: Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 Independent assurance: Internal Audit Business Continuity and Emergency Planning Sep '18 – Significant Assurance; 2019/20 Counter Fraud, Bribery and Corruption Annual Report; EU Exit Risk System Overview – Nottingham and Nottinghamshire System Dec '20; 360 Assurance Procurement Review Apr '21 – Significant Assurance		Positive

